Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
Authors:
- Mette S. van RamshorstMRMette S. van Ramshorst
- Suzana C. TeixeiraSTSuzana C. Teixeira
- Bas B. KoolenBKBas B. Koolen
- Kenneth E. PengelKPKenneth E. Pengel
- Kenneth G. GilhuijsKenneth G. Gilhuijs
- Jelle WesselingJWJelle Wesseling
- Renato A. Valdés OlmosRORenato A. Valdés Olmos
- Emiel J. RutgersEREmiel J. Rutgers
- Wouter V. VogelWVWouter V. Vogel
- Gabe S. SonkeGSGabe S. Sonke
- Marie-Jeanne T. Vrancken PeetersMPMarie-Jeanne T. Vrancken Peeters
Open Access
- 25 May 2017
- journal article
- research article
- Published by Springer Nature in Cancer Imaging
- Vol. 17 (1) , 1-8
Abstract
18F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic breast and axillary response at various time points during NST. Furthermore, we analysed if the combined metabolic response improves pathologic complete response (pCR) prediction compared to using the metabolic breast response alone. 18F-FDG PET/CT was performed at baseline (PET1), 2–3 weeks (PET2), and 6–8 weeks (PET3) of NST in patients with triple-negative (TN) and HER2-positive node-positive breast cancer. SUVmax and ∆SUVmax were determined separately for breast and axilla. Spearman’s correlation coefficients (r) between both localisations were calculated. The accuracy of pCR total (ypT0/is,ypN0) prediction using the metabolic response in breast, axilla or both was examined using logistic regression analysis. Hundred-five patients were included: 45 TN and 60 HER2-positive tumours. The metabolic response in breast and axilla correlated moderately in TN tumours (r = 0.57) using ∆SUVmax between PET1-PET3 and poorly in HER2-positive tumours (r = 0.49) using SUVmax at PET2. In TN tumours, metabolic breast response predicted pCR well without improvement after adding axillary response (c-index 0.82 versus 0.85, p = 0.63). In HER2-positive tumours, metabolic breast response predicted pCR poorly with improvement after adding axillary response (c-index 0.64 versus 0.72, p = 0.06). 18F-FDG PET/CT response during NST differs between breast and axilla. In TN tumours, pCR total prediction can be made independent of metabolic axillary response. In HER2-positive tumours, axillary response may improve pCR total prediction. These findings may help guide PET/CT-response-based changes during NST. NTR NTR1797 . Registered 29 May 2009, retrospectively registered.Keywords
Funding Information
- Center for Translational Molecular Medicine (Breast CARE (grant 03O-104))
This publication has 38 references indexed in Scilit:
- Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast CancerAnnals of Surgical Oncology, 2013
- Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the AxillaAnnals of Surgical Oncology, 2013
- Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early RelapseJournal of Nuclear Medicine, 2012
- Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breastJournal of Magnetic Resonance Imaging, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial ResultsAmerican Journal of Roentgenology, 2008
- Tumor-related prognostic factors for breast cancerCA: A Cancer Journal for Clinicians, 1997
- Applied Statistics for the Behavioral SciencesJournal of Educational Statistics, 1990